Innate Pharma (IPHA) Consolidated Net Income (2019 - 2025)

Innate Pharma (IPHA) has 7 years of Consolidated Net Income data on file, last reported at -$24.2 million in Q2 2025.

• Quarterly Consolidated Net Income rose 9.4% year-over-year to -$24.2 million in Q2 2025, while the trailing twelve-month figure through Dec 2025 was -$103.7 million (down 19.11% YoY) and the FY2022 annual result came in at -$133652.4, up 98.41% from the prior year.
• Consolidated Net Income rose to -$24.2 million in Q2 2025, from -$52.9 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $618509.1 in Q2 2023 to a low of -$52.9 million in Q4 2024.
• A 5-year average of -$16.5 million and a median of -$8.4 million in 2021 frame the typical range for Consolidated Net Income.
• The widest YoY moves for Consolidated Net Income: up 894.03% in 2023, down 5994.07% in 2023.
• Tracing IPHA's Consolidated Net Income over 5 years: stood at -$8.4 million in 2021, then surged by 98.41% to -$133652.4 in 2022, then sank by 5994.07% to -$8.1 million in 2023, then tumbled by 549.05% to -$52.9 million in 2024, then jumped by 54.3% to -$24.2 million in 2025.
• The last three Consolidated Net Income figures came in at -$24.2 million (Q2 2025), -$52.9 million (Q4 2024), and -$26.7 million (Q2 2024), per Business Quant data.